Document is current
Any future updates will be listed below
-
Authors
Kim, Soon-Chan
Kim, Ga-Hye
Park, Jae-Hyeon
Lee, Kyung-Hun
Koh, Jiwon
Kim, Tae-Yong
Lee, Dae-Won
Kim, Yu-Jin
Kim, Seongyeong
Park, Song-Yi
Min, Ahrum
Shin, Young-Kyoung
Im, Seock-Ah
Ku, Ja-Lok
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2021M3H9A1030151, NRF2022R1A5A102641311, 2022M3A9B6018217, 2021M3H9A1030151, NRF2022R1A5A102641311, 2022M3A9B6018217, 2021M3H9A1030151, NRF2022R1A5A102641311, 2022M3A9B6018217, 2021M3H9A1030151, NRF2022R1A5A102641311, 2022M3A9B6018217, 2021M3H9A1030151, NRF2022R1A5A102641311, 2022M3A9B6018217)
Korean Cell Line Research Foundation
National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (HA22C0111, HA22C0111, HA22C0111, HA22C0111, HA22C0111, HA22C0111, HA22C0111, HA22C0111, HA22C0111)
- License Information
-
More Information
Article History
Received: 18 November 2024
Accepted: 22 April 2025
First Online: 1 May 2025
Declarations
:
: The research protocol was reviewed and approved by the institutional review board of the Seoul National University Hospital (IRB No. 1102–098-357). The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients enrolled in this study.
: Not applicable.
: Seock-Ah Im received research fund from AstraZeneca, Boryung, Eisai, and Pfizer outside of this research work. Seock-Ah Im has advisory role for AstraZeneca, Eisai, Eli-Lilly, MSD, Novartis, Roche, Pfizer outside of this research work.
